The research and development (R&D) landscape for glucagon-like peptide-1 (GLP-1) receptor agonists and metabolic therapies is evolving beyond initial indications for treating glycemia in type 2 diabetes and weight reduction in obese/overweight with co-morbidities. Additional indications now include metabolic dysfunction-associated steatohepatitis (MASH), major adverse cardiovascular events (MACE) reduction, delay of renal disease progression, and treatment…
ADA conference roundup: GLP-1 trial results and researchers removed by police
Eli Lilly, Novo Nordisk, AstraZeneca and more announced recent GLP-1 clinical and preclinical data at the American Diabetes Association’s (ADA’s) national conference this week. The conference was eventful, with several experts being escorted out by police after handing out copies of an editorial criticizing the Trump administration’s science policies. The editorial was published in the…
Lilly’s retatrutide shows 28.3% weight loss, but increased side effects
Eli Lilly’s retatrutide, a triple hormone receptor agonist, has demonstrated an average weight loss of 28.3% over 80 weeks on the highest dose in Phase 3 trials. While this is more than the average weight loss of other GLP-1 drugs, the medicine comes with increased severity of side effects. Common side effects include nausea and…
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today. Retatrutide is an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist. The drug met the primary and key secondary endpoints, delivering superior A1C reduction and…
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase 2 trial in China, the company announced on Tuesday. UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G) and is being jointly developed with United Biotechnology. The trial was conducted by…
Lilly publishes promising phase 2 trial data for retatrutide, a potential obesity therapy
Lilly has announced promising data from its NCT 04881760 phase 2 study of retatrutide, a potential obesity drug. The drug candidate, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1 and glucagon receptors, was associated with significant weight loss, improved glycemic control and cardiovascular health. At 24 weeks, retatrutide (1 mg,…